114 related articles for article (PubMed ID: 17025026)
21. Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation.
Czubkowski P; Wierzbicka A; Socha P; Jankowska I; Pawłowska J
Ann Transplant; 2014 Nov; 19():604-8. PubMed ID: 25409773
[TBL] [Abstract][Full Text] [Related]
22. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
[TBL] [Abstract][Full Text] [Related]
23. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years.
Muirhead N; House A; Hollomby DJ; Jevnikar AM
Transplant Proc; 2003 Nov; 35(7):2391-4. PubMed ID: 14611965
[TBL] [Abstract][Full Text] [Related]
24. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
26. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A
Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721
[TBL] [Abstract][Full Text] [Related]
27. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients.
Baid-Agrawal S; Delmonico FL; Tolkoff-Rubin NE; Farrell M; Williams WW; Shih V; Auchincloss H; Cosimi AB; Pascual M
Transplantation; 2004 Apr; 77(8):1199-202. PubMed ID: 15114085
[TBL] [Abstract][Full Text] [Related]
29. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
[TBL] [Abstract][Full Text] [Related]
30. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
[TBL] [Abstract][Full Text] [Related]
31. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC; Henning AK; Holman J; First MR;
Transplantation; 2008 May; 85(9):1261-9. PubMed ID: 18475181
[TBL] [Abstract][Full Text] [Related]
32. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients.
Israni A; Brozena S; Pankewycz O; Grossman R; Bloom R
Am J Kidney Dis; 2002 Mar; 39(3):E16. PubMed ID: 11877596
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
[TBL] [Abstract][Full Text] [Related]
34. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression.
Baan CC; van Riemsdijk-van Overbeeke IC; Balk AH; Vantrimpont PM; Mol WM; Knoop CJ; Niesters HG; Maat LP; Weimar W
Clin Transplant; 2001 Aug; 15(4):276-83. PubMed ID: 11683823
[TBL] [Abstract][Full Text] [Related]
35. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
36. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
[TBL] [Abstract][Full Text] [Related]
37. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial.
Meier M; Nitschke M; Weidtmann B; Jabs WJ; Wong W; Suefke S; Steinhoff J; Fricke L
Transplantation; 2006 Apr; 81(7):1035-40. PubMed ID: 16612281
[TBL] [Abstract][Full Text] [Related]
38. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
[TBL] [Abstract][Full Text] [Related]
39. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus.
White M; Ross H; Haddad H; LeBlanc MH; Racine N; Pflugfelder P; Giannetti N; Davies R; Azevedo E; Isaac D; Burton J; Ferguson R; Genest J
Transplantation; 2006 Sep; 82(6):763-70. PubMed ID: 17006323
[TBL] [Abstract][Full Text] [Related]
40. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
Castel MA; Farrero M; Vallejos I; Cardona M; Regueiro A; Pérez-Villa F
Transplant Proc; 2011; 43(6):2244-6. PubMed ID: 21839245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
